Who's who

3 Houston innovators to know this week

Meet this week's Houston innovators to know. Courtesy photos

This week, some key Houston innovators to know include the CEO of a tech company that's demystifying Google's SEO, a local entrepreneur who just raised millions in funding, and the newest addition to the Houston innovation ecosystem.

Michael Umansky, CEO of Edgy Labs

Michael Umansky Ink and Edgy Labs

Courtesy of Edgy Labs

For years, Michael Umansky and the team at Edgy Labs have been figuring out the ins and outs of Google's algorithm for digital marketing purposes. If Edgy knows how Google ranks content, Edgy can provide the most optimized content out there for its clients.

But the Houston SEO experts also realized another group of people they can help: Content creators and writers. So, Edgy Labs created INK — a writing tool to help this group of individuals create the best and most optimized content without having to know anything about SEO.

"We envision a world where the content creators can control their own search destiny," Umansky says. "What we want to do is focus on empowering those writers to really take the power of search back into their own hands without having to be SEO experts." Read more.

Chris Buckner, CEO of Mainline

Courtesy of Mainline

Chris Buckner, CEO of Mainline, closed its series A at $6.8 million. Houston-based Work America Capital led the round, and the esports software startup will use the funds to grow its platform, event management customer base, and marketing efforts, as well as to hire developers, marketing, and sales talent.

"The world of esports and gaming is exploding; however, continuity in tournament organization is lacking, keeping the sport from really taking off in other viable and exciting markets," says Chris Buckner, Mainline CEO, in a news release. "Mainline gives brands the tools they need to run powerful esports programs that will evolve the quickly maturing industry to the benefit of players, students, and the greater esports ecosystem." Read more.

Jon Lambert, CEO of The Cannon Houston

Jon Lambert The Cannon

Courtesy of The Cannon

The Cannon Houston has had a big week — from celebrating its new flagship space to announcing its latest downtown outpost. And now, the coworking and startup hub has announced a new CEO: Jon Lambert.

"Lawson and his team have done an incredible job taking The Cannon vision and making it real. I'm happy to be part of the positive momentum and energy they have created. There has never been a better time for startups to enter the market, but achieving success has never been more challenging. The Cannon is playing a unique role in helping evolving companies navigate and accelerate their way through this journey." Read more.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted